Filing Flows › Xtant Medical Holdings (XTNT) › Q1 2026 › vs Q1 2025
Xtant Medical Holdings (XTNT) Q1 2026 vs Q1 2025 (year over year)
Xtant Medical Holdings's revenue fell $12.0M (-37%) from $32.9M in Q1 2025 to $20.9M in Q1 2026. The biggest changes: Spinal Implant −$5.9M (-53%); Orthobiologics −$2.5M (-14%).
Xtant Medical Holdings, Q1 2026: revenue $20.9M (-36% year over year), operating margin -14.0%, net loss $3.1M, operating cash flow −$2.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Orthobiologics | $15.6M | $18.1M | −$2.5M | -14% |
| Spinal Implant | $5.3M | $11.2M | −$5.9M | -53% |
| Revenue | $20.9M | $32.9M | −$12.0M | -37% |
| Net loss | $3.1M | −$58K | $3.1M | — |
| Costs & expenses | $24.0M | $32.9M | −$9.0M | -27% |
| Operating costs | $23.8M | $31.8M | −$8.0M | -25% |
| Interest & other, net | $139K | $1.0M | −$891K | -87% |
| Income tax | $27K | −$25K | $52K | — |
| Cost of revenue | $8.9M | $12.7M | −$3.7M | -30% |
| Research & development | $435K | $443K | −$8K | -2% |
| Sales & marketing | $8.2M | $11.2M | −$3.0M | -27% |
| General & admin | $6.3M | $7.5M | −$1.3M | -17% |
| Operating cash sources | $3.4M | $554K | $2.8M | +513% |
| Depreciation & amortization | $534K | $1.1M | −$540K | -50% |
| Share-based compensation | $746K | $758K | −$12K | -2% |
| Cash used in operations | $2.1M | −$1.3M | $3.4M | — |
| Net loss absorbed | $3.1M | −$58K | $3.1M | — |
| Working capital & other | $305K | $612K | −$307K | -50% |
Questions
How much did Xtant Medical Holdings's revenue grow year over year in Q1 2026?
Xtant Medical Holdings's revenue fell $12.0M (-37%) from $32.9M in Q1 2025 to $20.9M in Q1 2026.
What drove Xtant Medical Holdings's revenue change in Q1 2026?
Spinal Implant −$5.9M (-53%); Orthobiologics −$2.5M (-14%).